secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001601485-23-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio posts Q2 net loss $7.6M, cash $21.7M; reports interim AMPLIFY-201 data
-----------------------------------------------------------------------------

- Net loss $7.6M ($2.61/share) vs $7.3M; cash $21.7M at June 30 vs $6.2M at Dec 31, 2022.
- R&D expense $4.9M, G&A $2.8M (up vs $1.2M) due to reverse merger and public company costs.
- AMPLIFY-201 interim data: ELI-002 induced mKRAS T-cell response (56-fold avg); tumor biomarker reduced in 77% of patients.
- AMPLIFY-7P Phase 1A enrollment initiated for ELI-002 7P; Phase 1B RP2D initiation expected Q3 2023.
- Completed reverse merger in Q2 2023; common stock now trading on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/0001601485-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/angn-20230811.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer